Gareth Pryce Senior Research Fellow

 

Gareth Pryce obtained a degree in biology specialising in microbiology from the University of Bath. He has worked in many places and his research career has focused on studying immunological processes. He spent a number of years working at the Immunology Department at University College London. He them moved to the Institute of Psychiatry at Kings College London where he studied on leucocyte recruitment across the blood brain barrier. This was also investigated at the Institute of Ophthalmology, University College London, where he joined the group of Dr. David Baker.

Since that time he has been investigating a number of therapeutic avenues for the treatment of multiple sclerosis using experimental models and a number of approaches such as cannabinoid therapeutics and immunological tolerance are been developed towards the clinic.

Gareth Pryce has been involved in studies examining cannabinoids for the treatment of symptoms, the immune response and neuroprotection and is investigating methods to limit the psychoactive potential of cannabis-like molecules, whilst maintaining their therapeutic benefits.  

 

Image of presence of drug-exclusion pump on blood vessel in MS brain

 

Recent publications:

Pryce G and Baker D. Control of Spasticity in a Multiple Sclerosis Model is CB1, not CB2, cannabinoid receptor mediated. Brit J Pharmacol. 2007;150:519-525.

Maresz K et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T Cells.  Nat Medicine 2007;13:492-497.

Croxford JL et al. Cannabinoid-mediated neuroprotection, not immunosuppression, may be relevant to multiple sclerosis. J. Neuroimmunol. 2008; 193:120-129.